Abstract:Drug resistance significantly impairs the efficacy of AIDS therapy. Therefore, precise prediction of resistant viral mutants is particularly useful for developing effective drugs and designing therapeutic regimen. In this study, we applied a structure‐based computational approach to predict mutants of the HIV‐1 protease resistant to the seven FDA approved drugs. We analyzed the energetic pattern of the protease‐drug interaction by calculating the molecular interaction energy components (MIECs) between the drug and the protease residues. Support vector machines (SVMs) were trained on MIECs to classify protease mutants into resistant and nonresistant categories. The high prediction accuracies for the test sets of cross‐validations suggested that the MIECs successfully characterized the interaction interface between drugs and the HIV‐1 protease. We conducted a proof‐of‐concept study on a newly approved drug, darunavir (TMC114), on which no drug resistance data were available in the public domain. Compared with amprenavir, our analysis suggested that darunavir might be more potent to combat drug resistance. To quantitatively estimate binding affinities of drugs and study the contributions of protease residues to causing resistance, linear regression models were trained on MIECs using partial least squares (PLS). The MIEC‐PLS models also achieved satisfactory prediction accuracy. Analysis of the fitting coefficients of MIECs in the regression model revealed the important resistance mutations and shed light into understanding the mechanisms of these mutations to cause resistance. Our study demonstrated the advantages of characterizing the protease‐drug interaction using MIECs. We believe that MIEC‐SVM and MIEC‐PLS can help design new agents or combination of therapeutic regimens to counter HIV‐1 protease resistant strains. Proteins 2009. © 2008 Wiley‐Liss, Inc.

Activity prediction of HIV-1 protease inhibitors using support vector machine

Prediction of HIV‐1 Protease Inhibitors Using Machine Learning Approaches

Predicting Anti‐HIV‐1 Activities of HEPT‐analog Compounds by Using Support Vector Classification

Support Vector Machine (SVM) Models for Predicting Inhibitors of the 3' Processing Step of HIV-1 Integrase

Classification and Design of HIV-1 Integrase Inhibitors Based on Machine Learning.

HIV-1 Protease Cleavage Site Prediction Based on Two-Stage Feature Selection Method

Predicting Drug Resistance of the HIV‐1 Protease Using Molecular Interaction Energy Components

Activity Prediction of Angiotensin Converting Enzyme Inhibitors Based on the Quantitative Structure-Activity Relationship Method

HIV‐1 Protease Cleavage Site Prediction Based on Amino Acid Property

Classification of Src Kinase Inhibitors Based on Support Vector Machine

Activity prediction of hepatitis C virus NS5B polymerase inhibitors of pyridazinone derivatives

Predicting Human Immunodeficiency Virus Protease Cleavage Sites in Nonlinear Projection Space

Activity Prediction of Hormone-Sensitive Lipase Inhibitors Based on Machine Learning Methods

Prediction of Hepatitis C Virus Non-Structural Proteins 5B Polymerase Inhibitors Using Machine Learning Methods

Study on the Structure‐Activity Relationship of New Anti‐HIV Nucleoside Derivatives Based on the Support Vector Machine Method

Studies of Relationship Between Biological Activities and HIV Reverse Transcriptase Inhibitors by Multivariate Adaptive Regression Splines with Curds and Whey

Multistage virtual screening and identification of novel HIV-1 protease inhibitors by integrating SVM, shape, pharmacophore and docking methods

Prediction of Factor Xa Inhibitors by Machine Learning Methods

Support vector machines approach for predicting druggable proteins: recent progress in its exploration and investigation of its usefulness.

The Application of Deep Learning in the Prediction of HIV-1 Protease Cleavage Site

Prediction of Binding Rate of Drug to Human Plasma Protein Based on Heuristic Method and Support Vector Machine